CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TheSlowLane who wrote (74)	1/21/1997 2:52:00 PM
From: Bill Tomko	of 675

NMDA receptor is the same receptor that angle dust effects. that said the effects are claimed to be short term. IF IF IF it "works" then this should not be problem as like the saying goes " the ony good thing you can say about getting old is it beats the alternative". The real issue is no one knows the real cause or causes of reperfussion injury. They are apparently focused on NMDA receptors. others are focused on Na, and Ca channel blocker, NO blocking, O free radicals, L Gran. iniftration and some that I'm not aware of. Which is the correct one or ones?, NO ONE knows period. The best guess at this point is some combination. That said, given the lack of treatment options that exist today and the horrible affects of the process the FDA will likely approve anything with even marginal benifits. But while this area offers truely great potenial it is a crap shoot. CSNI being in phase III is as far along as anyone else. If they can show some marginal benifit I believe thay will get an approval and the stock will get a pop. I would evaluate the clinical results disclosed and be inclined to sell the news. pay your money and take your chance!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next